Cargando…

Alterations of gut microbiota and metabolome in early chronic kidney disease patients complicated with hyperuricemia

OBJECT: This study aims to investigate the changes in gut microbiota and metabolism of patients with chronic kidney disease (CKD) stage 1–2, as well as the potential impact of hyperuricemia (HUA) on these factors in CKD stage 1–2 patients. METHODS: In this study, fecal samples were collected from CK...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ping, Yang, Jianli, Chen, Yu, Zhu, Yifan, Tang, Yuyan, Xu, Xudong, He, Haidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560056/
https://www.ncbi.nlm.nih.gov/pubmed/37809388
http://dx.doi.org/10.1016/j.heliyon.2023.e20328
_version_ 1785117647507030016
author Liu, Ping
Yang, Jianli
Chen, Yu
Zhu, Yifan
Tang, Yuyan
Xu, Xudong
He, Haidong
author_facet Liu, Ping
Yang, Jianli
Chen, Yu
Zhu, Yifan
Tang, Yuyan
Xu, Xudong
He, Haidong
author_sort Liu, Ping
collection PubMed
description OBJECT: This study aims to investigate the changes in gut microbiota and metabolism of patients with chronic kidney disease (CKD) stage 1–2, as well as the potential impact of hyperuricemia (HUA) on these factors in CKD stage 1–2 patients. METHODS: In this study, fecal samples were collected from CKD stage 1–2 without HUA patients (CKD-N group), CKD stage 1–2 with HUA patients (CKD-H group), and healthy people controls (HCs group). The samples were then subjected to the microbiome (16S rRNA gene sequencing) and metabolome (liquid chromatography-tandem mass spectrometry) analyses. The multi-omics datasets were analyzed individually and integrated for combined analysis using various bioinformatics approaches. RESULTS: Gut microbial dysbiosis was found in CKD-N and CKD-H patients. At the phylum level, compared to HCs group, Bacteroidetes decreased but Proteobacteria increased in CKD-H group significantly. Fusobacteria in CKD-N group was significantly lower than HCs group. At genus level, [Eubacterium]_ventriosum_group, Fusobacterium, Agathobacter, Parabacteroides, and Roseburia significantly changed in CKD groups. [Ruminococcus]_gnavus_group was significantly lower in CKD-H group than CKD-N group. Moreover, the fecal metabolome of CKD-N and CKD-H altered significantly. d-glutamine and d-glutamate metabolism, arginine and proline metabolism, histidine metabolism, and lysine biosynthesis were down-regulated in the CKD-N group. Phenylalanine metabolism, arginine and proline metabolism, purine metabolism, and beta-alanine metabolism were up-regulated in the CKD-H group. There was a significant difference between the two CKD groups in phenylalanine metabolism. The abundance change of [Ruminococcus]_gnavus_group, [Eubacterium]_ventriosum_group, UCG-002, Alistipes, and Bifidobacterium had a close correlation with differential metabolites. CONCLUSION: The gut microbiota and metabolic status undergo significant changes in CKD patients compared to healthy people. Additionally, HUA has been found to impact the gut microbiota of CKD patients, as well as their metabolism. The close association between gut microbiota and metabolites suggests that the former plays a crucial role in metabolism.
format Online
Article
Text
id pubmed-10560056
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105600562023-10-08 Alterations of gut microbiota and metabolome in early chronic kidney disease patients complicated with hyperuricemia Liu, Ping Yang, Jianli Chen, Yu Zhu, Yifan Tang, Yuyan Xu, Xudong He, Haidong Heliyon Research Article OBJECT: This study aims to investigate the changes in gut microbiota and metabolism of patients with chronic kidney disease (CKD) stage 1–2, as well as the potential impact of hyperuricemia (HUA) on these factors in CKD stage 1–2 patients. METHODS: In this study, fecal samples were collected from CKD stage 1–2 without HUA patients (CKD-N group), CKD stage 1–2 with HUA patients (CKD-H group), and healthy people controls (HCs group). The samples were then subjected to the microbiome (16S rRNA gene sequencing) and metabolome (liquid chromatography-tandem mass spectrometry) analyses. The multi-omics datasets were analyzed individually and integrated for combined analysis using various bioinformatics approaches. RESULTS: Gut microbial dysbiosis was found in CKD-N and CKD-H patients. At the phylum level, compared to HCs group, Bacteroidetes decreased but Proteobacteria increased in CKD-H group significantly. Fusobacteria in CKD-N group was significantly lower than HCs group. At genus level, [Eubacterium]_ventriosum_group, Fusobacterium, Agathobacter, Parabacteroides, and Roseburia significantly changed in CKD groups. [Ruminococcus]_gnavus_group was significantly lower in CKD-H group than CKD-N group. Moreover, the fecal metabolome of CKD-N and CKD-H altered significantly. d-glutamine and d-glutamate metabolism, arginine and proline metabolism, histidine metabolism, and lysine biosynthesis were down-regulated in the CKD-N group. Phenylalanine metabolism, arginine and proline metabolism, purine metabolism, and beta-alanine metabolism were up-regulated in the CKD-H group. There was a significant difference between the two CKD groups in phenylalanine metabolism. The abundance change of [Ruminococcus]_gnavus_group, [Eubacterium]_ventriosum_group, UCG-002, Alistipes, and Bifidobacterium had a close correlation with differential metabolites. CONCLUSION: The gut microbiota and metabolic status undergo significant changes in CKD patients compared to healthy people. Additionally, HUA has been found to impact the gut microbiota of CKD patients, as well as their metabolism. The close association between gut microbiota and metabolites suggests that the former plays a crucial role in metabolism. Elsevier 2023-09-20 /pmc/articles/PMC10560056/ /pubmed/37809388 http://dx.doi.org/10.1016/j.heliyon.2023.e20328 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Liu, Ping
Yang, Jianli
Chen, Yu
Zhu, Yifan
Tang, Yuyan
Xu, Xudong
He, Haidong
Alterations of gut microbiota and metabolome in early chronic kidney disease patients complicated with hyperuricemia
title Alterations of gut microbiota and metabolome in early chronic kidney disease patients complicated with hyperuricemia
title_full Alterations of gut microbiota and metabolome in early chronic kidney disease patients complicated with hyperuricemia
title_fullStr Alterations of gut microbiota and metabolome in early chronic kidney disease patients complicated with hyperuricemia
title_full_unstemmed Alterations of gut microbiota and metabolome in early chronic kidney disease patients complicated with hyperuricemia
title_short Alterations of gut microbiota and metabolome in early chronic kidney disease patients complicated with hyperuricemia
title_sort alterations of gut microbiota and metabolome in early chronic kidney disease patients complicated with hyperuricemia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560056/
https://www.ncbi.nlm.nih.gov/pubmed/37809388
http://dx.doi.org/10.1016/j.heliyon.2023.e20328
work_keys_str_mv AT liuping alterationsofgutmicrobiotaandmetabolomeinearlychronickidneydiseasepatientscomplicatedwithhyperuricemia
AT yangjianli alterationsofgutmicrobiotaandmetabolomeinearlychronickidneydiseasepatientscomplicatedwithhyperuricemia
AT chenyu alterationsofgutmicrobiotaandmetabolomeinearlychronickidneydiseasepatientscomplicatedwithhyperuricemia
AT zhuyifan alterationsofgutmicrobiotaandmetabolomeinearlychronickidneydiseasepatientscomplicatedwithhyperuricemia
AT tangyuyan alterationsofgutmicrobiotaandmetabolomeinearlychronickidneydiseasepatientscomplicatedwithhyperuricemia
AT xuxudong alterationsofgutmicrobiotaandmetabolomeinearlychronickidneydiseasepatientscomplicatedwithhyperuricemia
AT hehaidong alterationsofgutmicrobiotaandmetabolomeinearlychronickidneydiseasepatientscomplicatedwithhyperuricemia